IL109993A0 - Ipsapirone medicament formulation - Google Patents
Ipsapirone medicament formulationInfo
- Publication number
- IL109993A0 IL109993A0 IL10999394A IL10999394A IL109993A0 IL 109993 A0 IL109993 A0 IL 109993A0 IL 10999394 A IL10999394 A IL 10999394A IL 10999394 A IL10999394 A IL 10999394A IL 109993 A0 IL109993 A0 IL 109993A0
- Authority
- IL
- Israel
- Prior art keywords
- ipsapirone
- medicament formulation
- medicament
- formulation
- ipsapirone medicament
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4319760A DE4319760A1 (en) | 1993-06-15 | 1993-06-15 | Ipsapiron drug preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
IL109993A0 true IL109993A0 (en) | 1994-10-07 |
Family
ID=6490360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10999394A IL109993A0 (en) | 1993-06-15 | 1994-06-13 | Ipsapirone medicament formulation |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0629402A1 (en) |
JP (1) | JPH06345649A (en) |
KR (1) | KR950000150A (en) |
CN (1) | CN1099263A (en) |
AU (1) | AU6345794A (en) |
CA (1) | CA2125620A1 (en) |
CZ (1) | CZ146494A3 (en) |
DE (1) | DE4319760A1 (en) |
FI (1) | FI942803A (en) |
HU (1) | HUT70759A (en) |
IL (1) | IL109993A0 (en) |
NO (1) | NO942228L (en) |
NZ (1) | NZ260732A (en) |
PL (1) | PL303822A1 (en) |
SK (1) | SK72494A3 (en) |
ZA (1) | ZA944187B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
OA11740A (en) * | 1998-12-24 | 2005-05-13 | Janssen Pharmaceutica Nv | Controlled release galantamine composition. |
WO2004103338A1 (en) * | 2003-05-19 | 2004-12-02 | Bioprogress Plc | Adhesives and film modifying compositions |
PL4062913T3 (en) * | 2020-09-02 | 2024-07-22 | Beijing Biostar Pharmaceuticals Co., Ltd. | Solid oral formulation of utidelone |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0386440T3 (en) * | 1989-02-11 | 1992-09-14 | Bayer Ag | Medicines with controlled release of active substance |
DD297767A5 (en) * | 1990-03-06 | 1992-01-23 | Bayer Aktiengesellschaft,De | MEDICINAL PRODUCTS WITH CONTROLLED ACTIVE INGREDIENTS |
JPH04360826A (en) * | 1991-06-07 | 1992-12-14 | Bayer Yakuhin Kk | Controlled release pharmaceutical preparation |
-
1993
- 1993-06-15 DE DE4319760A patent/DE4319760A1/en not_active Withdrawn
-
1994
- 1994-05-31 AU AU63457/94A patent/AU6345794A/en not_active Abandoned
- 1994-06-03 EP EP94108571A patent/EP0629402A1/en not_active Withdrawn
- 1994-06-09 JP JP6150640A patent/JPH06345649A/en active Pending
- 1994-06-10 CA CA002125620A patent/CA2125620A1/en not_active Abandoned
- 1994-06-13 IL IL10999394A patent/IL109993A0/en unknown
- 1994-06-13 PL PL94303822A patent/PL303822A1/en unknown
- 1994-06-13 FI FI942803A patent/FI942803A/en unknown
- 1994-06-13 NZ NZ260732A patent/NZ260732A/en unknown
- 1994-06-14 HU HU9401771A patent/HUT70759A/en unknown
- 1994-06-14 CZ CZ941464A patent/CZ146494A3/en unknown
- 1994-06-14 SK SK724-94A patent/SK72494A3/en unknown
- 1994-06-14 ZA ZA944187A patent/ZA944187B/en unknown
- 1994-06-14 KR KR1019940013308A patent/KR950000150A/en not_active Application Discontinuation
- 1994-06-14 NO NO942228A patent/NO942228L/en unknown
- 1994-06-15 CN CN94106657A patent/CN1099263A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
NZ260732A (en) | 1996-02-27 |
JPH06345649A (en) | 1994-12-20 |
FI942803A0 (en) | 1994-06-13 |
FI942803A (en) | 1994-12-16 |
EP0629402A1 (en) | 1994-12-21 |
CN1099263A (en) | 1995-03-01 |
PL303822A1 (en) | 1995-01-09 |
CZ146494A3 (en) | 1995-01-18 |
KR950000150A (en) | 1995-01-03 |
SK72494A3 (en) | 1995-04-12 |
ZA944187B (en) | 1995-02-08 |
AU6345794A (en) | 1994-12-22 |
CA2125620A1 (en) | 1994-12-16 |
NO942228L (en) | 1994-12-16 |
NO942228D0 (en) | 1994-06-14 |
HUT70759A (en) | 1995-10-30 |
DE4319760A1 (en) | 1994-12-22 |
HU9401771D0 (en) | 1994-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL102777A0 (en) | Pharmaceutical combination formulation | |
GB9402203D0 (en) | Pharmaceutical formulation | |
GB9114950D0 (en) | Pharmaceutical formulation | |
GB9311030D0 (en) | Pharmaceutical formulations | |
GB9323399D0 (en) | Pharmaceutical formulations | |
IL109993A0 (en) | Ipsapirone medicament formulation | |
GB9216061D0 (en) | Pharmaceutical combination formulation | |
GB2258613B (en) | Pharmaceutical diltiazem formulation | |
GB9418550D0 (en) | Drug formulation | |
ZA945962B (en) | Therapeutic formulation | |
GB9323487D0 (en) | Therapeutic formulation | |
GB9321346D0 (en) | Pharmaceutical formulation | |
GB9305439D0 (en) | Pharmaceutical formulation | |
GB9322907D0 (en) | Pharmaceutical formulation | |
GB9305437D0 (en) | Pharmaceutical formulation | |
GB9316250D0 (en) | Pharmaceutical formulation | |
GB9315016D0 (en) | Pharmaceutical formulation | |
GB9316253D0 (en) | Pharmaceutical formulation | |
GB9322906D0 (en) | Pharmaceutical formulation | |
GB9312705D0 (en) | Pharmaceutical formulation | |
GB9112974D0 (en) | Pharmaceutical formulation | |
GB9122115D0 (en) | Pharmaceutical formulation | |
GB9122114D0 (en) | Pharmaceutical formulation | |
GB9121798D0 (en) | Pharmaceutical formulation | |
GB9116467D0 (en) | Pharmaceutical formulation |